Cyclacel Pharmaceuticals

$0.4794
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0006 (-0.12%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell CYCC and other stocks, options, ETFs, and crypto commission-free!

About CYCC

Cyclacel Pharmaceuticals, Inc. Common Stock, also called Cyclacel Pharmaceuticals, is a clinical-stage biopharmaceutical company. Read More It uses cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The company builds a diversified biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

Employees
14
Headquarters
Berkeley Heights, New Jersey
Founded
1996
Market Cap
8.25M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
106.95K
High Today
$0.49
Low Today
$0.465
Open Price
$0.49
Volume
32.26K
52 Week High
$1.87
52 Week Low
$0.2813

Collections

CYCC News

ReutersAug 14

Edited Transcript of CYCC earnings conference call or presentation 13-Aug-19 8:30pm GMT

8

CYCC Earnings

-$0.20
-$0.10
$0.01
$0.11
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
-$0.11 per share

More CYCC News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.